arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

SOLIGENIX, INC.

SNGX
$0.39 ▲ +0.01 (+2.71%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

SOLIGENIX, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.0M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -73.8%
FCF / Share $-0.23
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-2.82M
↑ +12.7%
Operating Margin Operating profit as % of sales
-297.8%
↑ +38.3%
FCF / Share Free cash flow per share
$-0.23
↑ +61.7%
Long-Term Debt Long-term obligations
$1.01M
↓ -28.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
8
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters